US · TEM · MEDICAL - HEALTHCARE INFORMATION SERVICES
Tempus AI, Inc. (TEM) intrinsic value and stock valuation
$54.04as of 2026-11-21 · Mkt cap 8.18B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Tempus AI, Inc. DCF and intrinsic value
InvestorsCraft values TEM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TEM’s statements →
Tempus AI, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Centene Corp. (CNC) $63.78
- Medpace Holdings, Inc. (MEDP) $610.54
- Neurocrine Biosciences, Inc. (NBIX) $150.57
- The Cooper Companies, Inc. (COO) $58.88
- Fresenius Medical Care AG & Co. KGaA (FMS) $20.44
- Smith & Nephew plc (SNN) $29.83
- ICON Public Limited Company (ICLR) $186.71
- Universal Health Services, Inc. (UHS) $179.43
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.27B | $693.4M | $531.8M | $320.7M | $257.9M |
| Operating income | -$-252.87M | -$-691.08M | -$-196.08M | -$-265.44M | -$-243.71M |
| Net income | -$-245.03M | -$-705.81M | -$-214.12M | -$-289.81M | -$-259.19M |
| EPSd | -$-1.41M | -$-4.35M | -$-1.39M | -$-1.71M | -$-1.53M |
| Operating cash flow | -$-218.09M | -$-189.04M | -$-214.34M | -$-168.2M | -$-211.98M |
| Capital expenditure | -$-27.27M | -$-22.12M | -$-34.61M | -$-18.38M | -$-11.77M |
| Free cash flow | -$-245.35M | -$-211.17M | -$-248.95M | -$-186.58M | -$-223.75M |
| Total assets | $2.27B | $926.1M | $564.1M | $631.4M | $531.4M |
| Total debt | $1.33B | $468.1M | $488.1M | $433M | $239M |
| Net debt | $722.3M | $127.1M | $322.4M | $130.1M | -$-38.74M |
| Total equity | $491.3M | $56.3M | -$-1.38B | -$-1.13B | -$-807.49M |
| Cash and short-term investments | $755M | $448.3M | $197.6M | $302.9M | $277.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.27B | $693.4M | $531.8M | $320.7M | $257.9M |
| Cost of revenue | $473.9M | $312.3M | $245.7M | $190.5M | $174.2M |
| Gross profit | $797.9M | $381.1M | $286.2M | $130.2M | $83.6M |
| Research and development expenses | $319M | $316.8M | $185.5M | $162.3M | $128.4M |
| Selling, general and administrative expenses | $715.4M | $755.4M | $296.8M | $233.4M | $199M |
| Other expenses | $16.3M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.05B | $1.07B | $482.3M | $395.6M | $327.4M |
| Cost and expenses | $1.52B | $1.38B | $727.9M | $586.1M | $501.6M |
| Interest income | $12.6M | $11.1M | $7.6M | $3.03M | $620K |
| Interest expense | $70.3M | $53.7M | $46.9M | $21.9M | $15.2M |
| Depreciation and amortization | $102.3M | $37.2M | $33.3M | $30.4M | $23.9M |
| Ebitda | -$-118.51M | -$-610.42M | -$-133.33M | -$-236.85M | -$-219.52M |
| Operating income | -$-252.87M | -$-691.08M | -$-196.08M | -$-265.44M | -$-243.71M |
| Total other income/expenses, net | -$-43.84M | -$-14.46M | -$-17.75M | -$-24.3M | -$-15.48M |
| Income before tax | -$-296.71M | -$-705.54M | -$-213.83M | -$-289.75M | -$-259.19M |
| Income tax expense | -$-51.68M | $270K | $290K | $70K | $0.00 |
| Net income | -$-245.03M | -$-705.81M | -$-214.12M | -$-289.81M | -$-259.19M |
| Weighted average shares outstanding | $174.3M | $162.1M | $154.2M | $169.9M | $169.9M |
| Weighted average diluted shares outstanding | $174.3M | $162.1M | $154.2M | $169.9M | $169.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $755M | $448.3M | $197.6M | $302.9M | $277.7M |
| Net receivables | $320M | $154.8M | $94.5M | $88.7M | $82.2M |
| Inventory | $51.7M | $38.4M | $28.8M | $22.3M | $22.9M |
| Total current assets | $1.17B | $667.6M | $350.3M | $438.6M | $404M |
| Property, plant and equipment, net | $153.7M | $72.8M | $82.2M | $67.8M | $35.4M |
| Goodwill and intangible assets | $825.5M | $85.1M | $95.3M | $90.4M | $53.3M |
| Long-term investments | $86.6M | $91.5M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $1.11B | $258.5M | $213.7M | $192.7M | $127.4M |
| Total assets | $2.27B | $926.1M | $564.1M | $631.4M | $531.4M |
| Accounts payable | $82M | $53.8M | $54.4M | $46M | $33.8M |
| Short-term debt | $13.4M | $6.46M | $6.44M | $6.36M | $420K |
| Deferred revenue | $108.6M | $91.9M | $64.9M | $50.1M | $16.5M |
| Total current liabilities | $372.4M | $291.1M | $232.6M | $174.2M | $114.8M |
| Long-term debt | $1.31B | $461.6M | $481.7M | $426.7M | $238.5M |
| Deferred revenue, non-current | $28.4M | $30.6M | $16.8M | $35.1M | $0.00 |
| Total non-current liabilities | $1.41B | $578.7M | $1.71B | $1.59B | $1.22B |
| Capital lease obligations | $87.6M | $32.7M | $38.5M | $43.5M | $710K |
| Total liabilities | $1.78B | $869.8M | $1.95B | $1.76B | $1.34B |
| Common stock | $20K | $20K | $10K | $10K | $10K |
| Retained earnings | -$-2.4B | -$-2.15B | -$-1.4B | -$-1.14B | -$-807.49M |
| Accumulated other comprehensive income (loss) | $900K | $90K | $10K | $20K | -$-10K |
| Total equity | $491.3M | $56.3M | -$-1.38B | -$-1.13B | -$-807.49M |
| Total investments | $236.8M | $198.8M | $31.8M | $0.00 | $0.00 |
| Total debt | $1.33B | $468.1M | $488.1M | $433M | $239M |
| Net debt | $722.3M | $127.1M | $322.4M | $130.1M | -$-38.74M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-245.03M | -$-705.81M | -$-214.12M | -$-289.81M | -$-259.19M |
| Depreciation and amortization | $102.3M | $37.2M | $33.3M | $30.4M | $23.9M |
| Stock-based compensation | $124.8M | $534.1M | $0.00 | $0.00 | $560K |
| Change in working capital | -$-178.55M | -$-37.8M | -$-37.84M | $71.8M | $14.6M |
| Accounts receivable | -$-90.4M | -$-61.04M | -$-7.35M | -$-8.2M | $4.75M |
| Inventory | -$-3.37M | -$-9.54M | -$-6.56M | -$-1.31M | $14.7M |
| Accounts payable | -$-7.24M | -$-23.85M | -$-23.36M | -$-7.92M | -$-30.47M |
| Net cash provided by operating activities | -$-218.09M | -$-189.04M | -$-214.34M | -$-168.2M | -$-211.98M |
| Investments in property, plant and equipment | -$-21.05M | -$-22.12M | -$-34.61M | -$-18.38M | -$-11.77M |
| Acquisitions, net | -$-376.67M | -$-95.19M | -$-5.71M | -$-39.56M | -$-5.96M |
| Net cash used for investing activities | -$-398.36M | -$-130.39M | -$-40.31M | -$-57.94M | -$-21.72M |
| Common stock issued | $195.5M | $382M | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-3.04M | $0.00 | -$-3.6M | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-5.62M | -$-5.62M | -$-5.62M | -$-5.62M |
| Net cash used for financing activities | $884.1M | $494.3M | $117.6M | $251.4M | -$-2.04M |
| Net change in cash | $267.6M | $175.2M | -$-137.12M | $25.3M | -$-235.75M |
| Cash at end of period | $609.5M | $341.8M | $166.6M | $303.7M | $278.5M |
| Operating cash flow | -$-218.09M | -$-189.04M | -$-214.34M | -$-168.2M | -$-211.98M |
| Capital expenditure | -$-27.27M | -$-22.12M | -$-34.61M | -$-18.38M | -$-11.77M |
| Free cash flow | -$-245.35M | -$-211.17M | -$-248.95M | -$-186.58M | -$-223.75M |
Line items
Line items
Line items
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- CEO
- Eric Lefkofsky
- Employees
- 3.8K
- Beta
- 3.46
Explore
Frequently asked questions
What is the intrinsic value of Tempus AI, Inc. (TEM)?
Tempus AI, Inc. (TEM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TEM undervalued?
TEM trades at a price of $54.04 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.